No connection

Search Results

LNTH vs MIRM

LNTH
Lantheus Holdings, Inc.
NEUTRAL
Price
$80.59
Market Cap
$5.25B
Sector
Healthcare
AI Confidence
85%
MIRM
Mirum Pharmaceuticals, Inc.
BEARISH
Price
$96.49
Market Cap
$5.82B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
LNTH
23.63
MIRM
--
Forward P/E
LNTH
12.81
MIRM
-888.74
P/B Ratio
LNTH
4.78
MIRM
15.91
P/S Ratio
LNTH
3.4
MIRM
11.17
EV/EBITDA
LNTH
14.31
MIRM
2731.73

Profitability

Gross Margin
LNTH
61.1%
MIRM
80.77%
Operating Margin
LNTH
19.07%
MIRM
-3.07%
Profit Margin
LNTH
15.15%
MIRM
-4.48%
ROE
LNTH
21.45%
MIRM
-8.65%
ROA
LNTH
9.28%
MIRM
-1.83%

Growth

Revenue Growth
LNTH
4.0%
MIRM
49.8%
Earnings Growth
LNTH
--
MIRM
--

Financial Health

Debt/Equity
LNTH
0.57
MIRM
1.02
Current Ratio
LNTH
2.7
MIRM
2.67
Quick Ratio
LNTH
2.2
MIRM
2.46

Dividends

Dividend Yield
LNTH
--
MIRM
--
Payout Ratio
LNTH
0.0%
MIRM
0.0%

AI Verdict

LNTH NEUTRAL

LNTH exhibits strong operational health with a Piotroski F-Score of 7/9 and robust liquidity (Current Ratio 2.70), though it lacks an Altman Z-Score for bankruptcy benchmarking. While the company is highly profitable with an ROE of 21.45% and a consistent track record of earnings beats, the stock trades at a significant premium to its Graham Number ($35.98) and Intrinsic Value ($23.87). The bullish outlook is supported by a low Forward P/E of 12.81 and a positive analyst target of $91.38, but the current price is disconnected from deterministic value metrics.

Strengths
Strong financial health indicated by a Piotroski F-Score of 7/9
Excellent liquidity with a Current Ratio of 2.70 and Quick Ratio of 2.20
High profitability with 21.45% ROE and 61.10% Gross Margin
Risks
Significant valuation gap between current price ($80.59) and Graham Number ($35.98)
Modest year-over-year revenue growth of only 4.00%
Bearish technical trend (0/100) despite recent 6-month recovery
MIRM BEARISH

MIRM exhibits severe fundamental weakness with a Piotroski F-Score of 2/9, indicating poor financial health and operational inefficiency. While the company shows impressive revenue growth of 49.8% and strong gross margins, this is offset by a lack of profitability and an extremely stretched valuation (P/B of 15.91). There is a stark divergence between the 'strong_buy' analyst consensus and the bearish reality of aggressive insider selling by the CEO, CFO, and President. The combination of a bearish technical trend (10/100) and deteriorating deterministic scores suggests the current price is speculative and unsupported by fundamentals.

Strengths
Strong YoY revenue growth of 49.80%
Excellent gross margins at 80.77%
Healthy short-term liquidity with a current ratio of 2.67
Risks
Critically low Piotroski F-Score (2/9) indicating weak financial health
Aggressive insider selling across C-suite executives (CEO, CFO, President)
Extreme valuation multiples (Price/Book: 15.91, Price/Sales: 11.17)

Compare Another Pair

LNTH vs MIRM: Head-to-Head Comparison

This page compares Lantheus Holdings, Inc. (LNTH) and Mirum Pharmaceuticals, Inc. (MIRM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile